The leadless cardiac pacemakers market is expected to grow from $47.1 million in 2017 to $269.8 million by 2026, representing exceptional growth at a compounded annual growth rate (CAGR) of 21.9% from 2018 to 2026. Atrial fibrillation is the most common type of cardiac arrhythmia diagnosed globally. As per the latest research citations in the Global Burden of Disease (GBD) report, the global prevalence rate of atrial fibrillation is 191.3 per 100,000 people.
Leadless cardiac pacemakers are going to eventually replace traditional pacemakers on account of their inherent features such as small size, fewer surgical complications, extended battery life, no device dislodgement, and easy retrieval. Nanostim and wireless cardiac simulation systems will capture the market in the near future after FDA approval.
Market Synopsis
Easy implantation, low device dislodgement, and easy retrieval drive the market growth of the Micra transcatheter pacing system.
Micra transcatheter pacing systems (Medtronic, Plc.) are currently leading the type segment for leadless cardiac pacemakers. It received successful FDA approval in April 2016 owing to its inherent features, such as easy implantation, low device dislodgement, and easy retrieval. It is embedded in the right ventricle via the femoral venous access, which utilizes a steerable delivery sheath.
The nano sim leadless cardiac pacemaker system (St. Jude Medical, Inc.) was the first system to be implanted in humans for safety and efficacy studies during the LEADLESS clinical trial study. It recently had two major recalls related to premature battery failure and spontaneous docking button detachment. Both of these systems are restricted to single-chamber pacing, specifically ventricular pacing.
In the near future, dual chamber and multichambered leadless pacing systems will be critically studied in clinical trial studies. A wireless cardiac simulation system (EBR Systems, Inc.) is still under investigation; it employs a pulse generator that communicates with a leadless pacing electrode via acoustic energy.
The rising prevalence of cardiac arrhythmias, as well as the location of major players, are driving market growth in North America.
Currently, North America represents a share of 70% and is the global leader in the leadless cardiac pacemaker market. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), approximately 630,000 United States citizens die annually from heart disease, which corresponds to 1 in every four individuals.
The primary features contributing to its overwhelming growth are the rising prevalence of cardiac arrhythmias and the domicile of major players such as Medtronic, Plc., St. Jude Medical, Inc., and EBR Systems, Inc., etc. Europe holds a market share of 18% and is the second largest market in the leadless cardiac pacemaker market.
Rising public health awareness and an affordable reimbursement scenario are driving market growth in the European region for leadless cardiac pacemakers. Asia Pacific accounts for a 7% market share, primarily due to its huge population base suffering from cardiac complications and developing healthcare infrastructure.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is segmented by type and by geography.
Medical device manufacturers actively participating in the leadless cardiac pacemakers market are Boston Scientific Corporation, EBR Systems, Inc., Medtronic, Plc., Nanostim, Inc., and St. Jude Medical, Inc.
Key questions are answered in this report.
Which major players are manufacturing leadless cardiac pacemakers?
What are the disease etiology of cardiac arrhythmias and the global prevalence rate of atrial fibrillation?
What are the patient population and market size for the MICRA transcatheter pacing system?
What will be the future market trends pertaining to the leadless cardiac pacemaker market?
What are the shortcomings of Nanostim and wireless cardiac stimulation pacing systems, and when will they receive FDA approval?
Which factors are responsible for the dominance of the North American regional segment?
Frequently Asked Question:
The market for Leadless Cardiac Pacemakers Market is expected to reach USD$ 269.8 Mn in 2026.
The Leadless Cardiac Pacemakers Market is expected to see significant CAGR growth over the coming years, at 21.9%.
The report is forecasted from 2018 -2026.
The base year of this report is 2017.
Boston Scientific Corporation, EBR Systems, Inc., Medtronic, Plc., Nanostim, Inc., and St. Jude Medical, Inc. are some of the major players in the global market.
